Aptar scoops up two pharma services firms in $50m deal

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags Aptar Group Analytical testing Drug development

Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.

Headquartered in Crystal Lake, IL, Aptar​ provides a range of dispensing, sealing, and active packaging solutions and this week purchased the two companies for a combined enterprise value of approximately $50m.

Nanopharm provides analytical and drug development services with a focus on orally inhaled and nasal drug products and is located in Newport, UK, while Gibsonia, PA-based Gateway Analytical provides particulate detection and predictive analytical services to customers developing injectable medicines.

According to Aptar, the acquisitions are in line with the company’s strategy to expand its services portfolio.

The addition will enable the company to collaborate with customers earlier, supporting drug formulation and delivery.

Aptar has previously voiced plans to expand globally​ as part of a multi-year investment plan in response to expected growth in the injectable market driven by biologics and vaccines.

Related news

Show more

Related products

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us

Products

View more

Webinars